Evidence map›Paper›PMID 31806133›Full record

Trial reportJournal of the American College of Cardiology2019

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.

Dipak Kotecha, Simrat K Gill, Marcus D Flather, Jane Holmes, Milton Packer, Giuseppe Rosano, Michael Böhm, John J V McMurray, John Wikstrand, Stefan D Anker and 13 more

Erratum issued 2 registry-linked trialsOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of the American College of Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06249932 phase4recruitingstarted 2024, after this paper: background citation

The Safety and Efficacy of Empagliflozin in Patients with End-stage Renal Disease and Heart Failure with Reduced Ejection Fraction - a Randomized Controlled Trial

Ran2024Enrolled95Registered outcomes33Posted comparisons0ConditionsEnd Stage Renal Disease on Dialysis, Heart Failure With Reduced Ejection FractionArmsempagliflozin 25 mg, Placebo
PMID 30361677PMID 23859488PMID 30296931PMID 36576563PMID 34669059PMID 32865377PMID 32282987PMID 31780586PMID 31535829PMID 31434508PMID 31146814PMID 33719499other papers from this trial
Open the trial in the graph
NCT06249945 phase4recruitingstarted 2024, after this paper: background citation

The Safety and Efficacy of Empagliflozin in Patients With End-stage Renal Disease and Heart Failure With Preserved Ejection Fraction - a Randomized Controlled Trial

Ran2024Enrolled150Registered outcomes27Posted comparisons0ConditionsEnd Stage Renal Disease on Dialysis, Heart Failure With Preserved Ejection FractionArmsempagliflozin 25 mg, Placebo
PMID 30361677PMID 31504452PMID 31434508PMID 31146814PMID 30328645PMID 26861140PMID 23859488PMID 19007588PMID 31599363PMID 31780586PMID 31926856PMID 32061315other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
  13. Cardiometabolic Dysregulation and Heart Failure.Reviews in cardiovascular medicine · 2025
    Review
  14. Review
  15. Fractional excretion of sodium and 1-year cardiovascular mortality in acute decompensated heart failure, is there any relationship?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 17 institutions in 9 countries.

Dipak KotechaInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia. Electronic address: d.kotecha@bham.ac.uk.
Simrat K GillInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.
Marcus D FlatherNorwich Medical School, Faculty of Medicine and Health Science, University of East Anglia, Norwich, United Kingdom.
Jane HolmesCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
Milton PackerBaylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas.
Giuseppe RosanoCentre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.
Michael BöhmKardiologie, Angiologie und Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, Homburg/Saar, Germany.
John J V McMurrayRobertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom.
John WikstrandWallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Stefan D AnkerDepartment of Cardiology, Charite Campus Virchow-Klinikum, Berlin, Germany.
Dirk J van VeldhuisenUniversity of Groningen, Department of Cardiology, University Medical Centre Groningen, RB Groningen, the Netherlands.
Luis ManzanoInternal Medicine Department, Hospital Universitario Ramón y Cajal, Universidad de Alcalá (IRYCIS), Plaza de San Diego, Madrid, Spain.
Thomas G von LuederCentre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria, Australia; Department of Cardiology, Oslo University Hospital, Oslo, Norway.
Alan S RigbyHull York Medical School, Faculty of Health Sciences, University of Hull, Kingston-upon-Hull, United Kingdom.
Bert AnderssonDepartment of Cardiology, Sahlgrenska University Hospital and Gothenburg University, Gothenburg, Sweden.
John KjekshusRikshospitalet University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway.
Hans WedelHealth Metrics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Frank RuschitzkaKlinik fur Kardiologie, UniversitätsSpital Zürich, Zürich, Switzerland.
John G F ClelandInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Kevin DammanUniversity of Groningen, Department of Cardiology, University Medical Centre Groningen, RB Groningen, the Netherlands.
Josep RedonINCLIVA Biomedical Research Institute, Valencia, Spain.
Andrew J S CoatsCentre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.
Beta-Blockers in Heart Failure Collaborative Group
Istituto di Ricovero e Cura a Carattere Scientifico San RaffaeleUniversity of Birmingham · GBUniversity of Glasgow · GBUniversity of Gothenburg · SEBaylor University Medical Center · USCharité - Universitätsmedizin Berlin · DEINCLIVA Health Research Institute · ESOslo University Hospital · NOSahlgrenska University Hospital · SEUniversidad de Alcalá · ESUniversitätsklinikum des Saarlandes · DEUniversity Medical Center Groningen · NLUniversity of East Anglia · GBUniversity of Groningen · NLUniversity of Hull · GBUniversity of Oslo · NOUniversity of Oxford · GB

Funding

Cancer Research UK 27294Department of Health CDF-2015-08-074
6 · The paper itself

Abstract

backgroundModerate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.

objectivesThis study sought to investigate patient prognosis and the efficacy of beta-blockers according to renal function using estimated glomerular filtration rate (eGFR).

methodsAnalysis of 16,740 individual patients with left ventricular ejection fraction <50% from 10 double-blind, placebo-controlled trials was performed. The authors report all-cause mortality on an intention-to-treat basis, adjusted for baseline covariates and stratified by heart rhythm.

resultsMedian eGFR at baseline was 63 (interquartile range: 50 to 77) ml/min/1.73 m

conclusionsPatients with heart failure, left ventricular ejection fraction <50% and sinus rhythm should receive beta-blocker therapy even with moderate or moderately severe renal dysfunction.

Indexed as

Adrenergic beta-AntagonistsAgedCause of DeathComorbidityDisease ProgressionDouble-Blind MethodFemaleGlomerular Filtration RateHeart FailureHumansMaleMiddle AgedPrognosisRenal InsufficiencyStroke VolumeSurvival RateAdrenergic beta-Antagonistsbeta-blockersheart failuremortalityrenal impairment

Identifiers

PMID31806133
OpenAlexW2990282381

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.